LY 3300054

Drug Profile

LY 3300054

Alternative Names: Anti-PD-L1 checkpoint antibody - Eli Lilly; LY3300054

Latest Information Update: 14 Jul 2016

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD274 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 01 Jun 2016 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT02791334)
  • 01 Jun 2016 Preclinical trials in Solid tumours in USA (IV) before June 2016
  • 01 Jun 2016 Eli Lilly plans the phase Ia/Ib PACT trial for Solid tumours (Monotherapy, Combination therapy, Second-line therapy or greater, Late-stage disease) in USA, Belgium, Canada, France, Israel, South Korea, Netherlands, Spain, Taiwan, Mexico and South Africa (IV) (NCT02791334)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top